US FDA successfully inspects Shusun's plant

Shasun Pharmaceuticals Ltd has successfully completed US FDA inspection at its manufacturing facility at Dudley England. The US FDA audit was held on first week of November 2014. “On completion of the inspection the USFDA inspector concluded that the facility, systems and practices comply with USFDA requirements with no observations reported on the form 483,” said Shasun in a press release.
 
The Chennai-headquartered Shasun Pharmaceuticals is one of the leading Indian manufacturers of APIs and formulations, catering to global customers, with state-of-the-art capabilities and facilities. Shasun offers formulation and generic manufacturing services at its Indian sites together with a contract research and manufacturing services for APIs in India and UK.